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esis	 that	 the	spread	of	 resistant	Schistosoma mansoni	may	be	 limited	by	 life-	history	
costs	not	present	in	susceptible	counterparts.	S. mansoni	parasites	from	a	praziquantel-	
susceptible	(S),	a	praziquantel-	resistant	(R)	or	a	mixed	line	of	originally	resistant	and	
susceptible	 parasites	 (RS)	were	 exposed	 to	 a	 range	 of	 praziquantel	 doses.	 Parasite	
numbers	at	each	life	stage	were	quantified	in	their	molluscan	intermediate	and	murine	
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1  | INTRODUCTION
Parasite	populations	often	exhibit	 considerable	genetic	variability	 in	
their	natural	 tolerance,	or	 acquired	 resistance,	 to	drugs	 (Pollitt,	 Sim,	
Salathe,	 &	 Read,	 2015).	 Evolutionary	 theory	 suggests	 that	 one	 po-
tential	 mechanism	 for	 maintaining	 such	 diversity,	 particularly	when	
considering	 resistance,	 is	 fitness	 costs	 associated	 with	 such	 resis-
tance	 compared	 to	 susceptible	 lines	 (Hughes	 &	 Andersson,	 2015).	




&	Zaghloul,	 2008).	However,	 convincing	demonstrations	of	 costs	of	





Schistosoma mansoni,	which	 causes	 intestinal	 schistosomiasis	 across	
sub-	Saharan	Africa	and	in	pockets	of	South	America	and	the	Middle	
East	 (GBD	2016).	Resistance	 to	praziquantel	 treatment	was	 first	 re-







Chiodini,	 2003;	Melman	 et	al.,	 2009;	Wang,	Wang,	 &	 Liang,	 2012),	
praziquantel	resistance	still	has	a	limited	recorded	distribution	(Botros	
et	al.,	2005;	Wang,	Dai,	Li,	Shen,	&	Liang,	2010;	Xu	et	al.,	2015).	Whilst	
observed	 low	 cure	 rates	 can	be	 caused	by	 a	 range	of	 factors	 other	
than	resistance,	such	as	high	intensities	of	infection,	high	rates	of	re-








a	diverse	complex	 life	cycle	 (Botros	&	Bennett,	2007);	 (ii)	 low	MDA	
coverage	and	untreated	 life	cycle	 stages	outside	of	 the	human	host	
provide	high	levels	of	refugia	for	susceptible	parasites	to	persist	(King,	
Muchiri,	&	Ouma,	2000;	Park,	Haven,	Kaplan,	&	Gandon,	2015);	 (iii)	




that	 praziquantel	 resistance	 could	 take	 over	 a	 decade	 to	 establish	
due	 to	 a	 combination	 of	 these	 limiting	 factors	 (King	 et	al.,	 2000).	




appropriate	 interventions	 at	 a	 public	 health	 level.	 Such	 studies	 also	
help	understand	more	broadly	the	complex	processes	involved	in	the	
evolution	of	resistance	in	multihost	systems.
Here,	 using	 a	 laboratory	 host–parasite	 system,	 we	 explore	 the	
hypothesis	that	there	are	costs	associated	with	resistance	which	may	
act	to	limit	the	spread	of	praziquantel-	resistant	parasites.	Whilst	some	
S. mansoni	 isolates	can	maintain	resistance	in	the	 laboratory	without	
praziquantel	 pressure	 (Cioli	 et	al.,	 2004),	 other	 S. mansoni	 isolates	
have	been	reported	to	revert	to	susceptibility	in	as	few	as	six	mouse	
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net	costs	would	be	dependent	on	both	(ii)	praziquantel	dose	and	(iii)	
selection	generation.





S. mansoni	 parasite	 lines	 (praziquantel-	resistant	 (R),	 susceptible	 (S)	





maintenance	of	 the	 line.	 Parasites	 from	each	 treatment	 group	were	
maintained	for	four	generations	 (G1–G4),	using	four	definitive	hosts	
(female	Tuc	Ordinary	(TO)	Harlan®	adult	mice)	and	50	indeterminate	
hosts	(30	Biomphalaria glabrata and 20 B. alexandrina)	in	each	genera-
tion	(Figure	1a	and	Appendix	Fig.	S1).
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To	 initiate	 the	 asexual	 stage	 of	 the	 schistosome	 life	 cycle,	 50	
Biomphalaria	 snails	 (30	 B. glabrata and 20 B. alexandrina)	 per	 treat-
ment	group	in	5	ml	spring	water	were	each	exposed	to	six	miracidia	
that	were	pooled	 from	all	mice	within	 the	same	experimental	 treat-
ment	group.	Miracidia	remaining	after	2	hr	of	exposure	were	counted	
and	discarded.	Snail	 survival	was	 recorded	weekly.	Each	week,	 from	
3	weeks	post-	parasite	exposure	(to	allow	for	maturation	of	sporocysts	













2.2 | Parasite life cycle state- space model
To	understand	the	complexities	governing	potential	variation	in	life-	
history	 traits	 and	 trade-	offs	 in	 S. mansoni	 parasite	 lines,	 and	 how	
these	may	be	impacted	by	low	and	high	praziquantel	doses,	we	mod-
elled	the	life	cycle	of	the	three	lines	of	S. mansoni	across	generations.	
We	 developed	 two	 Bayesian	 stage-	structured	 population	 models	




illustrates	 the	stages	of	 the	worm	 life	cycle	as	 they	were	modelled	














ies	 strengthens	 our	 inference.	 Finally,	 similar	model	 structures	 can	
be	used	for	both	the	sexual	and	asexual	component	of	the	life	cycle,	





(A)	 and	 the	adults	 that	 survive	 can	 reproduce	and	 lay	eggs.	Once	
exposed	 to	 freshwater,	 these	 eggs	 hatch	 into	miracidia	 (M).	With	
the	within-	mouse	model	 (Figure	1),	we	estimate	the	adult	survival	
(sA)	 and	 fecundity	 (λ)	 rates	 for	 each	 parasite	 line	 across	 the	 four	
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generations	and	the	impact	of	low	and	high	praziquantel	doses	on	
these	 two	 traits.	 Specifically,	 we	 model	 the	 number	 of	 cercariae	
in	replicate	 i	from	generation	t	that	became	established	inside	the	
mouse	 and	 survived	 to	 full	 adult,	 nA,i,t	 as	 a	 binomial	 process	 pa-
rameterized	 by	 the	 number	 of	 cercariae	 each	 mouse	 is	 exposed	
to	 (nA,i,t = 220 in t = 1 and nA,i,t = 110 in t	=	2,3,4)	 and	 probability	
sA,i,t	describing	the	combined	establishment	and	adult	survival	rate	
(Figure	1),	which	was	expressed	as	a	 logit	 function	of	 low	or	high	
drug	dose:
The	baseline	daily	 survival	of	each	parasite	 line	 (l)	β0,l	was	given	
a	prior	distribution	derived	from	a	beta	distribution	with	mean	0.85	
and	variance	0.01	 (transformed	 to	 the	 logit	 space;	 see	derivation	 in	


























2006)	 (mean	=	365*0.5*0.34	=	62.05);	 that	 is,	 the	 fecundity	 rate	
is	 an	estimate	of	 the	number	of	eggs	 laid	by	one	unexposed	pair	
of	worms	 that	 hatch	 and	 become	miracidia.	The	 coefficients	λ1,l,t 
and λ2,l,t	governing	the	impact	of	low	and	high	treatment	were	es-
timated	 using	 normal	 distribution	 priors	with	 mean	 0	 and	 preci-














survival	 rate	expressed	as	a	 logit	 function	of	a	parasite	 line-	specific	
baseline	 assuming	 a	 prior	 based	on	 a	 logit	 of	 a	 beta	 distribution	 of	





















The	 within-	snail	 model	 is	 similar	 to	 the	 within-	mouse	 model.	






mean 0.85 and variance 0.01.
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0.1 and variance 0.01.











and	 every	 100th	 iteration	 kept	 for	 analysis	 (thinning).	 Convergence	











resistance.	 Net	 fitness	 was	 estimated	 within	 each	 generation	 and	





administrated	 to	 the	definitive	host.	Thirdly,	 to	 investigate	whether	
there	was	selection	for	resistance	under	drug	pressure,	the	individual	




3.1 | Life- history traits but not trade- offs differ 
between parasite lines in control groups
In	the	untreated	control	groups,	the	number	of	observed	adult	worms,	













average	 survival	 across	generations	 in	S	 line	was	0.65	and	 in	R	 line	
was	0.71.	RS	parasites	had	the	most	similar	rates	of	adult	worm	sur-








survival	 and	 fecundity	 rates	 were	 estimated	 for	 all	 control	 groups	















demonstrated	 a	 clear	 trade-	off	 between	 establishment	 and	 shedding	
rates,	where	higher	 establishment	 rates	 led	 to	 lower	 cercariae	output	
(Figure	3g–i,	black	lines).	However,	these	trade-	offs	were	not	strong	for	
either	R	or	S	lines	when	infecting	B. glabrata	(Figure	3d,	f,	black	lines).
3.2 | Praziquantel dose- dependent changes in life- 





that	praziquantel	 treatment	 in	 the	previous	mouse	host	did	not	 im-
pact	 the	 average	 number	 of	 cercariae/miracidium	 neither	 in	 snail	
species	(Figure	2c)	nor	across	generations	(Appendix	S2	Fig.	S2).	Our	
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models	 confirmed	 these	 observations.	 Specifically,	 the	 within-	snail	
model	estimated	a	negligible	impact	of	praziquantel	on	cercarial	pro-



















negatively	 impacted	 by	 50	mg/kg	 praziquantel	 compared	 to	 other	
lines,	but	 fecundity	was	 least	 affected	at	 the	 same	dosage	 in	nearly	








3.3 | Evidence of selection during the experiment
Our	within-	mouse	model	 showed	 that	 praziquantel	 treatment	 low-
ered	 worm	 density	 by	 impacting	 both	 adult	 survival	 and	 fecundity	










Baseline	(control) G1 0.62	(0.59–0.75) 0.71	(0.66–0.80) 0.65	(0.57–0.86)
G2 0.70	(0.62–0.79) 0.77	(0.70–0.91) 0.66	(0.60–0.84)
G3 0.51	(0.40–0.71) 0.78	(0.74–0.87) 0.89	(0.85–0.93)
G4 0.80	(0.74–0.90) 0.81	(0.77–0.90) 0.65	(0.61–0.74)
%	Reduction	low	
praziquantel
G1 29.86	(22.7–37.3) 38.97	(33.0–45.1) 30.09	(19.1–42.3)
G2 25.33	(15.4–35.8) 19.86	(13.1–26.5) 28.86	(20.2–38.2)
G3 9.05	(0.0–20.1) 23.01	(16.9–28.9) 44.58	(33.5–54.0)
G4 21.10	(13.4-	29.0) 9.65	(0.0–19.5) 0	(0–1.1)
%	Reduction	high	
praziquantel
G1 53.24	(44.0–59.3) 8.88	(0.4–17.5) 52.39	(42.2–59.3)
G2 30.63	(17.6–39.7) 31.74	(23.2–39.4) 48.84	(37.5–57.6)
G3 8.17	(0.0–19.7) 22.69	(16.1–29.7) 49.19	(42.1–55.7)
G4 12.54	(2.3–23.0) 19.43	(12.6–25.2) 40.48	(32.5–47.7)
Fecundity
Baseline	(control) G1 123	(105–141) 117	(101–134) 127	(114–141)
G2 65	(53–81) 89	(70–111) 120	(107–140)
G3 115	(94–136) 75	(55–98) 40	(33–54)
G4 77	(69–86) 85	(70–108) 129	(110–149)
%	Reduction	low	
praziquantel
G1 27.69	(17.97–36.81) 0.0	(0.0–0.0) 0.0	(0.0–5.38)
G2 0.0	(0.0–8.59) 2.97	(0.0–17.05) 4.34	(0.0–16.20)
G3 0.0	(0.0–5.99) 0.0	(0.0–0.0) 0.0	(0.0–0.0)
G4 31.02	(13.81–46.57) 40.76	(27.74–53.53) 0.0	(0.0–8.41)
%	Reduction	high	
praziquantel
G1 4.98	(0.0–14.11) 42.30	(31.13–50.78) 14.58	(2.28–23.03)
G2 44.21	(26.83–58.00) 21.79	(2.46–36.21) 10.56	(0.0–19.11)
G3 3.78	(0.0–17.11) 21.35	(9.84–34.56) 37.29	(24.45–50.80)












Understanding	 changes	 in	 life-	history	 traits	 and	 potential	 costs	 of	
drug	resistance	in	parasites	is	important	for	managing	the	emergence	
of	resistance	and	implementing	suitable	control	measures	in	regions	
where	resistance	 is	 found.	 In	this	study,	we	use	state-	space	models	
(SSMs)	to	quantify	these	costs	using	empirical	data	from	a	laboratory	
study	of	 an	 indirectly	 transmitted	parasite.	We	show	 that	 it	 is	pos-
sible	to	measure	differences	in	life-	history	traits	in	parasite	suscepti-
ble	and	resistant	lines,	providing	a	proof	of	concept	for	implementing	
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praziquantel-	treated	 groups	 and	 across	 generations,	 the	 parameter	
estimates	generated	from	the	model	enabled	us	to	show	that	variation	
between	groups	can	be	better	understood	when	shown	as	life-	history	
trade-	offs.	 Higher	 fecundity	 in	 untreated	 parasites	 was	 associated	









support	 for	 the	hypothesis	 that	 costs	of	 resistance	 limit	 the	 spread	
of	 praziquantel-	resistant	 phenotypes	 in	 natural	 populations,	 it	 does	
suggest	that	life	histories	are	altered	in	R	parasites	when	exposed	to	
praziquantel,	but	not	altered	in	the	S	parasite	lines.
Using	 a	 S. mansoni	 model,	 our	 findings	 indicate	 that	 measur-
ing	 within-	host	 parasite	 life-	history	 trade-	offs	 captures	 better	 the	
complexity	 of	 host–parasite	 interactions	 which	 are	 affected	 by	
praziquantel,	than	empirical	measures	of	individual	 life-	history	traits.	
In	 comparison	 with	 classical	 statistical	 methods	 (Lamberton	 et	al.,	
2017),	 the	SSM	was	able	 to	differentiate	 life-	history	 traits	between	
parasite	 lines.	 This	 is	 likely	 because	 this	 SSM	method	 explicitly	 in-












































































































































































ument	damage	 (Greenberg,	 2013).	Juvenile	worms	 are	not	 killed	by	
praziquantel,	and	it	is	only	after	they	reach	sexual	maturity	that	they	
are	 praziquantel-	susceptible	 (Cioli	&	Pica-	Mattoccia,	 2003).	A	 study	












in	 the	 field,	with	 each	 person	 normally	 treated	 once	 a	year	 or	 less.	
Therefore,	an	alternative	explanation	for	why	resistant	parasites	have	
not	 yet	 become	more	widespread	 is	 that	 although	 R	 parasite	 lines	
will	 be	 able	 to	 establish	within	 a	 human,	 their	 lower	 overall	 fecun-
dity	makes	it	less	likely	that	“R”	genes	would	be	transmitted	onwards.	








(Greenberg,	2013),	 stress	 response	genes	 (Hines-	Kay	et	al.	2012)	or	
other	genetic	or	epigenetic	factors.
Previous	work	has	documented	lower	cercarial	production	in	sev-
eral	 resistant	 lines	 (William	et	al.,	 2001).	Although	 the	R	 and	S	par-






alone,	 indicating	 that	we	may	 be	 reporting	 phenotypic	 or	 inducible	
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B. glabrata	may	reflect	its	role	as	their	natural	host	even	in	laboratory	
conditions.	Additionally,	 the	 larger	 variation	 in	 estimates	 associated	
with	B. alexandrina	may	be	due	to	a	larger	genetic	variability	within	the	
host	species	compared	with	the	laboratory-	adapted	B. glabrata.
In	 the	 snail	 host,	 there	were	 few	differences	observed	between	
lines	and	no	effect	of	indirect	praziquantel	treatment	on	parasite	life	
histories.	 Cercarial	 production	 was	 not	 different	 between	 R	 and	 S	
parasite	 lines;	however	 in	early	generations	of	RS,	 cercarial	 produc-
tion	was	higher	than	S	and	R	individually.	Overall,	the	mixed	RS	lines	




mating	occurs.	As	Schistosoma	 species	 rapidly	 lose	genetic	variation	
when	passaged	in	the	laboratory	(Gower	et	al.,	2007;	Stohler,	Curtis,	
&	Minchella,	2004),	the	increased	fitness	of	RS	may	be	explained	by	













life	 cycle	 in	 the	 treated	 selected	 lines,	 as	 this	would	not	have	been	





macokinetic	 differences	with	 adults	 on	whom	 the	 drug	was	 initially	
trialled	 (Bustinduy	 et	al.,	 2016;	 Olliaro,	 Delgado-	Romero,	 &	 Keiser,	









limitations	 of	 the	 design.	We	 saw	no	differences	 in	 definitive	 hosts	





Although	 the	 two	 strains	 that	were	 used	 (MOC-	S	 and	 EE2-	R)	 have	
significantly	different	susceptibilities	to	praziquantel	and	the	levels	of	
susceptibility	are	stable	over	laboratory	passages	even	in	the	absence	
of	 drug	 treatment	 (Sabra	&	Botros,	 2008;	William	 et	al.,	 2001),	 po-
tential	costs	may	have	been	reduced	under	previous	laboratory	selec-
tion.	 In	 addition,	 although	EE2-	R’s	 stability	 is	 important	 to	 compare	
between	a	susceptible	and	resistant	parasite,	it	might	be	that	the	sta-
bility	 is	 inherently	 linked	 to	not	having	high	costs	of	 resistance.	For	


















These	 results	 highlight	 the	 importance	 of	 monitoring	 multiple	 life-	





schistosomiasis	 at	 the	 current	 scale	 and	 frequency	 raises	 concerns	
about	 the	emergence	of	drug	 resistance	 in	 the	parasites	 (Bergquist,	
Utzinger,	 &	 Keiser,	 2017;	 Botros	 &	 Bennett,	 2007;	Webster	 et	al.,	
2014),	 but	 such	detailed	 studies	would	 be	 impossible	 to	 achieve	 in	
the	 field	 under	 natural	 (human	 definitive	 host)	 conditions.	 Our	 re-
sults	thereby	provide	important	insights	and	have	theoretical	and	ap-
plied	implications	and	applications	for	future	schistosomiasis	control	
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